Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2024-07-15
Completion Date
2024-11-30
Last Updated
2024-07-15
Healthy Volunteers
Yes
Conditions
Interventions
HDM1002 100 mg QD
HDM1002 tablets 100mg daily, 12weeks
HDM1002 200 mg QD 12weeks
HDM1002 tablets 200mg daily, 12weeks
HDM1002 400 mg QD 12weeks
HDM1002 tablets 400mg daily, 12weeks
Placebo
Matching placebo will be provided